AbbVie Inc.’s branded Humira (adalimumab) holds a 98% share of the US adalimumab market by volume nine months after the first biosimilar version of the drug became available, according to a quarterly biosimilars report from the biosmilar manufacturer Samsung Bioepis Co., Ltd..
Key Takeaways
- AbbVie’s Humira has demonstrated notable resiliency against biosimilar competition in the first year.
The market share figure highlights the strength of AbbVie’s branded drug to stand up against biosimilar competition in the US...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
